The European Commission has granted marketing authorization to Boehringer Ingelheim for SENVELGO (active ingredient: velagliflozin), a groundbreaking development in the treatment of feline diabetes across Europe. SENVELGO stands out as the world’s first once-daily liquid oral solution specifically designed to reduce hypoglycemia in cats with non-insulin-dependent diabetes mellitus.

This innovative medication simplifies the management of feline diabetes, enabling cat owners to easily integrate the treatment into their daily routines. Administered once daily either with food or directly into the cat’s mouth, SENVELGO has demonstrated effectiveness in improving diabetic symptoms in cats, reducing elevated blood glucose levels, and minimizing the risk of clinical hypoglycemic events. Its liquid form is preferred by cats and owners alike, based on various studies.

Dr. Stijn Niessen, President of the European College of Veterinary Internal Medicine (ECVIM), highlighted the impact of SENVELGO on feline diabetes management in Europe. He emphasized its ability to reduce the complexity and burden of treatment, notably diminishing the risk of clinical hypoglycemia and the need for continuous glucose monitoring. This advancement is expected to significantly improve the quality of life for both cats and their owners.

Feline diabetes mellitus, a common metabolic disorder in cats, has been a challenge due to the increasing cat population and the complexity of existing treatments. Unfortunately, a high proportion of diabetic cats are euthanized within the first year of diagnosis, partly due to the complexity of their care. SENVELGO addresses these challenges by offering a more accessible and efficient treatment option.

Eric Haaksma, Head of Animal Health Global Innovation at Boehringer Ingelheim, expressed the company’s commitment to transforming scientific advancements into practical solutions for animals and their owners. The launch of SENVELGO underscores this commitment, enhancing the care of diabetic cats and simplifying the responsibilities of their owners.

Following its authorization in the European Union, SENVELGO is set to be rolled out across EU countries. Already approved in Switzerland, Great Britain, and the US, Boehringer Ingelheim plans to expand the availability of SENVELGO globally, pending regulatory approvals in various countries.

  Boehringer Ingelheim, Diabetes mellitus, Dr. Stijn Niessen, Eric Haaksma, SENVELGO, velagliflozin, Veterinary Pharmaceuticals